top of page

Solid FY22 Marked by Broad-Based Growth

ERGOMED, a services business which includes an industry-leading suite of specialist pharmacovigilance solutions, reported FY22 results broadly in line with Edison Group's expectations. Group revenues grew 22.5% y-o-y to £145.3m, underpinned by sustained demand for both the CRO and PV segments and supported by the ADAMAS acquisition and foreign exchange benefit. Adjusted EBITDA rose 11.5% y-o-y, although margins were comparatively lower (19.5% versus 21.4% in FY21) due to previously flagged incremental investments in technology and senior management hires. The order book remained robust at £295m (up 23.1% over FY21), boding well for medium-term sales potential. Year-end net cash of £19.1m was an improvement over the £12m reported in H122 (after the £24.2m net cash purchase of ADAMAS in February 2022) and, with £80m in undrawn credit facilities, Ergomed remains well-capitalised to fund future growth. Edison Group have made minor adjustments to their estimates and roll forward their model. Edison has upgraded their valuation slightly to 1,577p/share from 1,573p/share previously.



c4a53afbf62a1fcfa69d0171d1943437
.pdf
Download PDF • 302KB


2 views0 comments

Recent Posts

See All

Comments


bottom of page